Medical treatment for gastro-entero-pancreatic neuroendocrine tumours

• 作者: Rossana Berardi Francesca Morgese Mariangela Torniai Agnese Savini Stefano Partelli Silvia Rinaldi Miriam Caramanti Consuelo Ferrini Massimo Falconi Stefano Cascinu
• 来源期刊: 世界胃肠肿瘤学杂志：英文版（电子版）
• 学科: 医学
• 关键词: NEUROENDOCRINE neoplasms of the gastro-entero-pancreatic system Chemotherapy Targeted agents SOMATOSTATIN ANALOGUES EVEROLIMUS SUNITINIB
• 年，卷（期）: 2016,（4）
• 页码范围: 389-401
• 页数: 13页
• 分类号: R735

摘要

Gastro-entero-pancreatic neuroendocrine neoplasms(GEPNENs) represents a various family of rare tumours. Surgery is the first choice in GEP-NENs patients with localized disease whilst in the metastatic setting many other treatment options are available. Somatostatin analogues are indicated for symptoms control in functioning tumours. Furthermore they may be effective to inhibit tumour progression. GEP-NENs pathogenesis has been extensively studied in the last years therefore several driver mutations pathway genes have been identified as crucial factors in their tumourigenesis. GEP-NENs can over-express vascular endothelial growth factor(VEGF), basic-fibroblastic growth factor, transforming growth factor(TGF-α and-β), platelet derived growth factor(PDGF), insulin-like growth factor-1(IGF-1) and their receptors PDGF receptor, IGF-1 receptor, epidermal growth factor receptor, VEGF receptor, and c-kit(stem cell factor receptor) that can be considered as potential targets. The availability of new targeted agents, such as everolimus and sunitinib that are effective in advanced and metastatic pancreatic neuroendocrine tumours, has provided new treatment opportunities. Many trials combing new drugs are ongoing.